Formosa Laboratories (TPE:4746) Piotroski F-Score: 6 (As of Jun. 27, 2026) — Near Median


TPE:4746 Formosa Laboratories Inc TPE:4746
70 GF Score
Price NT$50.80
GF Value NT$98.73
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Formosa Laboratories Piotroski F-Score?

Formosa Laboratories TPE:4746 -2.31% 70 Piotroski F-Score is 6 as of Jun. 27, 2026, which is at its 10-year median of 6.00. GuruFocus rates TPE:4746 with a GF Score™ of 70/100 and a GF Value™ of NT$98.73 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 981 Drug Manufacturers companies, Formosa Laboratories ranks better than 79.2% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Formosa Laboratories has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Formosa Laboratories's Piotroski F-Score or its related term are showing as below:

TPE:4746' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Formosa Laboratories was 8. The lowest was 2. And the median was 6.

Formosa Laboratories  (TPE:4746) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Formosa Laboratories Piotroski F-Score Related Terms


Formosa Laboratories Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Formosa Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Formosa Laboratories Piotroski F-Score Chart

Formosa Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 6.00 7.00 6.00 6.00

Formosa Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 4.00 5.00 6.00

TPE:4746 vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Formosa Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Formosa Laboratories Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Formosa Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Formosa Laboratories's Piotroski F-Score falls into.


TPE:4746
70GF Score
Formosa Laboratories Inc TPE:4746
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was 120.545 + -150.864 + 324.105 + 147.321 = NT$441 Mil.
Cash Flow from Operations was 441.253 + 299.342 + 276.588 + 298.064 = NT$1,315 Mil.
Revenue was 1143.721 + 1242.828 + 1160.622 + 1304.186 = NT$4,851 Mil.
Gross Profit was 480.899 + 517.03 + 491.772 + 542.401 = NT$2,032 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(13895.381 + 13873.569 + 13581.772 + 13543.984 + 13833.317) / 5 = NT$13745.6046 Mil.
Total Assets at the begining of this year (Dec24) was NT$13,895 Mil.
Long-Term Debt & Capital Lease Obligation was NT$2,032 Mil.
Total Current Assets was NT$5,549 Mil.
Total Current Liabilities was NT$2,900 Mil.
Net Income was -96.019 + 283.929 + 22.371 + -53.013 = NT$157 Mil.

Revenue was 1134.103 + 1214.512 + 1030.885 + 1351.546 = NT$4,731 Mil.
Gross Profit was 542.07 + 522.8 + 424.16 + 559.686 = NT$2,049 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(13636.191 + 13397.047 + 13407.407 + 13938.88 + 13895.381) / 5 = NT$13654.9812 Mil.
Total Assets at the begining of last year (Dec23) was NT$13,636 Mil.
Long-Term Debt & Capital Lease Obligation was NT$2,752 Mil.
Total Current Assets was NT$5,868 Mil.
Total Current Liabilities was NT$2,356 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Formosa Laboratories's current Net Income (TTM) was 441. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Formosa Laboratories's current Cash Flow from Operations (TTM) was 1,315. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=441.107/13895.381
=0.03174487

ROA (Last Year)=Net Income/Total Assets (Dec23)
=157.268/13636.191
=0.01153313

Formosa Laboratories's return on assets of this year was 0.03174487. Formosa Laboratories's return on assets of last year was 0.01153313. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Formosa Laboratories's current Net Income (TTM) was 441. Formosa Laboratories's current Cash Flow from Operations (TTM) was 1,315. ==> 1,315 > 441 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=2032.482/13745.6046
=0.14786414

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=2752.16/13654.9812
=0.20154989

Formosa Laboratories's gearing of this year was 0.14786414. Formosa Laboratories's gearing of last year was 0.20154989. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=5549.1/2900.325
=1.91326834

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=5868.02/2355.793
=2.49088948

Formosa Laboratories's current ratio of this year was 1.91326834. Formosa Laboratories's current ratio of last year was 2.49088948. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Formosa Laboratories's number of shares in issue this year was 122.1. Formosa Laboratories's number of shares in issue last year was 121.896. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2032.102/4851.357
=0.41887291

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2048.716/4731.046
=0.43303658

Formosa Laboratories's gross margin of this year was 0.41887291. Formosa Laboratories's gross margin of last year was 0.43303658. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=4851.357/13895.381
=0.34913451

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=4731.046/13636.191
=0.34694777

Formosa Laboratories's asset turnover of this year was 0.34913451. Formosa Laboratories's asset turnover of last year was 0.34694777. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+0+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Formosa Laboratories has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Formosa Laboratories (TPE:4746) has a Piotroski F-Score of 6 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Formosa Laboratories and its competitors. This is near median its historical median of 6.00. Over the past decade, Formosa Laboratories' Piotroski F-Score has ranged from 2.00 to 8.00. According to the industry distribution chart, Formosa Laboratories ranks #204 out of 981 companies in the Drug Manufacturers industry, placing it in the top 20.8%.
Is Formosa Laboratories' Piotroski F-Score too high?
Formosa Laboratories' current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Formosa Laboratories' value of 6 is 20% above this industry median. Based on the distribution chart, Formosa Laboratories ranks #204 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Formosa Laboratories has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Formosa Laboratories' Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Formosa Laboratories ranks #204 out of 981 companies for Piotroski F-Score. This places Formosa Laboratories in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Formosa Laboratories' value of 6 is 20% above this benchmark. Historically, Formosa Laboratories' own Piotroski F-Score has ranged from 2.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Formosa Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Formosa Laboratories's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Formosa Laboratories and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Formosa Laboratories's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formosa Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Formosa Laboratories (TPE:4746) is currently considered Possible Value Trap. The stock's GF Value™ is NT$98.73, compared to a current price of NT$50.80 — trading 48.5% below its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 20% above the Drug Manufacturers industry median of 5.00. Formosa Laboratories' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Formosa Laboratories (TPE:4746), the current Piotroski F-Score is 6 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Formosa Laboratories (TPE:4746) Overvalued in 2026?

Based on GuruFocus' analysis, Formosa Laboratories stock appears to be undervalued. The current stock price of NT$50.80 is trading 48.5% below its estimated GF Value™ of NT$98.73. GuruFocus considers Formosa Laboratories to be Possible Value Trap.

Key valuation signals for TPE:4746:

  • Piotroski F-Score: 6 (near median its 10-year median of 6.00)
  • GF Value™: NT$98.73 vs. price of NT$50.80 (48.5% below fair value)
  • GF Score™: 70/100 with 3 warning signs
  • Industry Position: 20% above the Drug Manufacturers median (#204 of 981)

No single metric tells the full story. See the TPE:4746 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Formosa Laboratories Business Description

Address No. 36-1, Heping Street, Luzhu disctrict, Taoyuan, TWN, 338002
Formosa Laboratories Inc is mainly engaged in the wholesale and manufacturing of active pharmaceutical ingredients, as well as ultraviolet absorbers. The company geographically operates in India, Taiwan, Netherlands, Switzerland, Germany, Japan, China, Canada, United States, and Others.
70GF Score

Get the complete analysis for TPE:4746

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$50.80
Price
NT$98.73
GF Value